ArticleFrontiers in pediatrics2025
Pharmacovigilance-based 12-year post-marketing safety analysis of quadrivalent influenza vaccines in children: a VAERS surveillance study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Quadrivalent influenza vaccines (QIVs) are extensively administered to children for seasonal influenza prevention. However, comprehensive long-term evaluations of post-marketing safety remain limited. Methods: We conducted a comprehensive 12-year pharmacovigilance analysis utilizing data from the Vaccine Adverse Event Reporting System (VAERS) for individuals under 18 years receiving six FDA-approved QIVs between 2013 and 2024, representing three distinct platforms: four egg-based inactivated vaccines (Afluria, Fluarix, FluLaval, Fluzone), one cell culture-based inactivated vaccine (Flucelvax), and one live-attenuated intranasal vaccine (FluMist). Disproportionality analyses using reporting odds ratios (ROR) and Bayesian information component (IC) were employed to identify safety signals. Safety signals were considered statistically significant when the lower bound of the 95% confidence interval for ROR exceeded 1.0 and the lower bound of the IC (IC025) exceeded 0. Results: Of the 15,458 reported adverse events, 5.29% (95% CI: 4.95-5.65) were classified as serious, including 67 fatalities. Guillain-Barré syndrome (GBS) emerged as a statistically significant safety signal (42 cases; ROR = 1.71, 95% CI: 1.25-2.35; IC025 = 0.28). Among specific QIV products, Flucelvax demonstrated the lowest proportion of serious adverse events (2.35%). Notably, reporting volumes decreased by 42% during the COVID-19 pandemic. Conclusion: This pharmacovigilance analysis demonstrates generally favorable safety profiles for pediatric QIVs, with cell culture formulations showing superior safety characteristics. The extremely low absolute risk of Guillain-Barré syndrome supports continued routine pediatric influenza vaccination while highlighting the importance of platform-specific safety monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.